Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Moderna 3Q Revenues up 6% | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Moderna 3Q Revenues up 6%

Earlier launch of the updated COVID-19 vaccine drives higher sales in the U.S.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Moderna  
3Q Revenues: $1.9 billion (+6%) 
3Q Earnings: $13 million (loss of $3.6 billion 3Q23)
YTD Revenues: $2.3 billion (-44%)
YTD Loss: $2.4 billion (loss of $4.9 billion) 
Comments: The company reported $1.8 billion in Spikevax sales in the quarter, up 4 % which includes $1.2 billion of U.S. sales and $0.6 billion of international sales, driven by higher sales in the U.S. market following the earlier launch of the updated COVID-19 vaccine. RSV vaccine mRESVIA had $10 million in sales in the quarter, which were lower than anticipated.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters